Dr. Reddy's Laboratories (RDY) reported fiscal Q3 earnings Thursday of $0.20 per diluted share, up from $0.19 a year earlier.
Three analysts polled by FactSet expected $0.21.
Revenue for the quarter ended Dec. 31 was $977 million, compared with $843 million a year earlier.
Analysts surveyed by FactSet expected $950.5 million.
RDY shares were down 5.2% in recent trading.
Price: 14.31, Change: -0.79, Percent Change: -5.20
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。